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p38MAPKHepatocyte growth factor (HGF) and its receptor,Met, are key determinants of distinct developmental processes.
Although HGF exerts cardio-protective effects in a number of cardiac pathologies, it remains unknown whether
HGF/Met signaling is essential for myocardial development and/or physiological function in adulthood. We
therefore investigated the requirement of HGF/Met signaling in cardiomyocyte for embryonic and postnatal
heart development and function by conditional inactivation of the Met receptor in cardiomyocytes using the
Cre-α-MHC mouse line (referred to as α-MHCMet-KO). Although α-MHCMet-KOmice showed normal heart de-
velopment and were viable and fertile, by 6 months of age, males developed cardiomyocyte hypertrophy, asso-
ciated with interstitial ﬁbrosis. A signiﬁcant upregulation in markers of myocardial damage, such as β-MHC and
ANF, was also observed. By the age of 9 months, α-MHCMet-KO males displayed systolic cardiac dysfunction.
Mechanistically, we provide evidence of a severe imbalance in the antioxidant defenses in α-MHCMet-KO hearts
involving a reduced expression and activity of catalase and superoxide dismutase, with consequent reactive ox-
ygen species accumulation. Similar anomalieswere observed in females, althoughwith a slower kinetics.We also
found that Met signaling down-regulation leads to an increase in TGF-β production and a decrease in p38MAPK
activation, which may contribute to phenotypic alterations displayed in α-MHCMet-KO mice. Consistently, we
show that HGF acts through p38α to upregulate antioxidant enzymes in cardiomyocytes. Our results highlight
that HGF/Met signaling in cardiomyocytes plays a physiological cardio-protective role in adult mice by acting
as an endogenous regulator of heart function through oxidative stress control.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
The hepatocyte growth factor (HGF) receptor, Met, is a tyrosine ki-
nase receptor expressed in a wide variety of cell types. It regulates34 91 394 1779.
ool of Medicine, University of
y, Department of Medicine and
lack Family Stem Cell Institute,
ights reserved.several cellular functions, including proliferation, scattering, differentia-
tion and survival, either during development or under some pathologi-
cal conditions [1–3]. Upon HGF binding, Met is autophosphorylated in
different tyrosine residues, leading to the recruitment of several SH2-
domain containingproteins through themultifunctional docking site lo-
cated in its carboxy-terminal tail [4]. Both HGF and Met are essential
during development as shown by defects in placenta, liver, muscle,
and nerves [5–10]. The embryonic lethality of met mutants imposes
the use of conditional inactivation strategies to explore the HGF/Met
functional requirement during embryogenesis and adulthood.
Several studies have been performed to uncover the HGF/Met prop-
erties in the heart. It has been shown that HGF protects rats from myo-
cardial infarction [11] and/or ischemia/reperfusion injury [12]. Post-
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ing and heart function in mice [13]. In addition, HGF improves heart
functionality and promotes proliferation of myocardial progenitor cells
in doxorubicin-induced cardiomyopathy [14]. It also prevents heart
ﬁbrosis, remodeling and dysfunction in a hamster model of cardiomy-
opathy [15]. In other models of cardiac damage, HGF also inhibits
ﬁbrosis and additionally stimulates angiogenesis [16]. Together, these
ﬁndings indicate that HGF/Met axis exerts a cardio-protective role
under pathological conditions. In vitro studies have shown that HGF in-
duces the expression of cardiacmarkers inmesenchymal stem cells [17]
and increases cardiac differentiation of embryonic stem cells [18]. In
addition, stem cells express HGF, which improves its survival and that
of cardiomyocytes and favors angiogenesis [16]. Both HGF and Met are
expressed in cardiac myocytes during early cardiogenesis [19,20]. In
a mouse model of HGF supra-physiological expression, it has been
shown that neonatal cardiomyocytes express Met and respond to HGF
by increasing proliferation [21]. However, it remains unknownwhether
endogenous activity levels of HGF/Met are required for heart develop-
ment and/or physiology after birth.
In this study, we have genetically evaluated the role played by the
HGF/Met axis in developing and adult hearts using a conditional
knock-out mouse model lacking Met signaling in cardiomyocytes. In
particular, we conditionally deleted Met in cardiomyocytes by combin-
ing met ﬂoxed mice [22] with a transgenic line expressing the Cre
recombinase under the control of the α-myosin heavy chain (α-MHC)
promoter [23]. The α-MHC promoter is active in mouse embryos
throughout the myocardium starting from E8 [24]. Previous reports
have shown that by E12.5, α-MHC is highly expressed in atria and to a
lesser extent in the ventricles, whereas its expression increases in the
ventricles after birth [25]. Therefore, the α-MHC-Cre line allows c-met
inactivation in cardiomyocytes at early heart developmental stages.
Using the cardiomyocyte conditional Met knock-out, we have found
that Met signaling in cardiomyocytes appears to be dispensable for
heart development. However, it is required to protect cardiomyocytes
from oxidative stress, thus preventing cardiomyocyte hypertrophy,
heart ﬁbrosis, and heart dysfunction in adult mice. Together, these stud-
ies unveil that HGF/Met signaling in cardiomyocytes is a key regulator
for proper heart function.
2. Materials and methods
2.1. Generation of cardiomyocyte c-met knock-out mice and genotyping
The animals used in our research program were handled in compli-
ance with the institutional and European Union guidelines for animal
care and welfare. All mouse lines were maintained and bred at the
UCM facility, allowed food and water ad libitum and routinely screened
for pathogens in accordance with FELASA (Federation of European Lab-
oratory Animal Science Associations) procedures.
c-met ﬂox/ﬂox (wt) mouse line (in a CD1 genetic background),
which carries c-met alleles with exon 16 ﬂanked by loxP sites, was
obtained from Dr. S. Thorgeirsson [22]. This mouse was crossed with
α-MHC-Cre transgenic mouse in CD1 background (obtained from
Dr. M. D. Schneider [23]) to generate α-MHC-Cre/+: c-met ﬂox/+
mice, which were then crossed with c-met ﬂox/ﬂox mice. Cre-mediated
excision led to a null allele for c-met, which encodes an inactive Met re-
ceptor only in cardiomyocytes. Mice genotyping was performed by PCR
analysis (Supplemental methods).
2.2. RT-qPCR analysis
After the isolation of total RNA, DNA and proteins using AllPrep
DNA/RNA/Protein Mini Kit, RNA was reverse transcribed using Super-
Script III RT kit (Quiagen, 18080) to generate cDNA. Then, real time
PCRwasperformed using speciﬁc primers (see Supplementalmethods).
Quantiﬁcation was performed calculating RQ (2−ΔΔCt), so referring thevalues to control mice (Supplemental methods). An Invitrogen custom
RNA proﬁling by RT-qPCR was performed for the analysis of anti- and
pro-ﬁbrotic genes and those involved in reactive oxygen species (ROS)
metabolism (Supplemental methods).
2.3. Western-blot analysis
Western-blot analysis was carried out as previously described [26].
Proteins were separated by electrophoresis using Anderson or SDS–
PAGE gels, and transferred to nitrocellulose membranes that were
probed with the following antibodies: catalase (Sigma, C0979), super-
oxide dismutase-2 (SOD-2) (Upstate Biotech, 06-984), β-actin (Sigma
A5441), c-Met (Santa Cruz Biotechnology sc-260), phospho-c-Met
(Tyr 1230/1234/1235, Millipore 07-810) cytochrome c (BD 556433),
porin (Sigma V2139), phospho-p38MAPK (Cell Signaling, 9211), and
p38α (Santa Cruz Biotechnology sc-535).
2.4. Histology
Hearts were processed for histology using conventional techniques
involving paraformaldehyde ﬁxation and parafﬁn embedding. The
degree of interstitial ﬁbrosis was assessed by image analysis onMallory's
trichrome stained tissue sections (see Supplemental methods). Laminin
immunostaining of heart sections was done to delineate the
cardiomyocyte proﬁles, measuring their areas with the ImageJ analysis
package. Apoptotic cardiomyocytes were detected by using anti-
desmin (Sigma, D1033) and anti-active caspase-3 antibodies (Promega,
G74819).
2.5. ROS detection and quantiﬁcation
Reactive oxygen species (ROS) accumulation in hearts was detected
by staining of frozen sections with 1 μM 2-hydroethidine (in PBS).
The sections were then washed with PBS, mounted and analyzed by
ﬂuorescence microscopy. The number of stained nuclei was counted
on digitalized images using ImageJ software. Alternatively, in hearts
from 9-month-old mice, lipid peroxidation was determined by
immunolocalization of 4-OH-Nonenal (Alpha Diagnostics, HNE11-S) in
parafﬁn sections. Stained areas were assessed on digitalized images
using ImageJ software.
Carbonylated proteinswere quantiﬁed as an indirectmeasurement of
ROS [27]. Heart extracts were treated with 2,4-dinitrophenylhydrazine
or maintained untreated (blank). Then, proteins were precipitated with
TCA and absorbance at 360 nm was determined. The concentration of
carbonylated proteins was calculated upon correction with the blanks
and referred to protein content (Supplemental methods).
2.6. Measurement of catalase, SOD, and cytochrome c oxidase activities
Catalase activity was measured by quantiﬁcation of peroxide de-
composition spectrophotometrically at 240 nm. Superoxide dismutase
(SOD) activity was quantiﬁed using a Kit (BioVision) (Supplemental
methods). Cytochrome c oxidase activitywas determined by quantiﬁca-
tion of cytochrome c oxidation spectrophotometrically at 550 nm.
2.7. Electrocardiographic measurements in conscious mice
using radiotelemetry
Telemetric electrocardiogram (ECG) recordings in conscious mice
were carried out using an implantable telemetry system with ECG
transmitters (ETA-F10) (Data Sciences International, St. Paul, MN,
USA). Recordings were taken every 3 h, 5 min/each, over a 24 h period
and analyzed using ECG-auto software supplied by Data Systems (see
extensive description in Supplemental methods).
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Fig. 1. Conditional deletion of c-met in cardiomyocytes allows normal development and function of the heart in mice. a: Left panel: Representative PCR analysis showing a deletion (del)
speciﬁc fragment (650 bp) from the Cre-recombined allele detected in E15.5 embryonic hearts from α-MHCMet-KO mice after c-met exon 16 deletion and the ﬂoxed (ﬂx) fragment
(380 bp) present in met ﬂox/ﬂox hearts without Cre recombination (named as Metﬂ/ﬂ or control) (n = 5). Right panel: Western blot analysis of Met protein levels in hearts from
E15.5 embryos. b and c: Heart sections from wt and α-MHCMet-KO E15.5 embryos (b) and P2 newborn mice (c) stained with hematoxylin/eosin (scale bars: 250 μM for b top panel
and c, and 50 μM for b low panel) (n = 10).
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Transthoracic echocardiography was performed on lightly anesthe-
tized mice using a Vivid 7 (GE Medical Systems) cardiac ultrasound
machine equipped with a 10- to 14-MHz transducer il3L (GE Medical
Systems), as previously described [28]. Measurements of chamber
dimensions and cardiac function were made ofﬂine (EchoPac Software,
GE Medical Systems). Structural and functional heart parameters werecalculated as previously described [28] (see extensive description in
Supplemental methods).
2.9. Assays in cardiomyocytes derived cell lines
Cardiomyocyte cell lines (wt and p38α−/−) were generated from
E9.5 immortomouse embryos expressing a temperature-sensitive large
T antigen (LTAg) [29]. Before the experiments, cells were transferred to
2207M. Arechederra et al. / Biochimica et Biophysica Acta 1832 (2013) 2204–221537 °C in the absence of IFN-γ to abolish LTAg expression. Neonatal
cardiomyocyte cell lines were obtained by immortalization of neonatal
mice (P4) cardiomyocytes by transfection with LTAg. For the experi-
ments, all the cell lines were maintained in a low serum medium
(2%) and treated with the Met inhibitor SU11274 (5 μM) or TGF-β
(1 ng/mL) in the presence or absence of HGF (30 ng/mL, 16 h pretreat-
ment) or N-acetyl cysteine (2.5 mM) for 1–4 days as indicated.g
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used, and alternatively, ANOVA test was carried out for comparisons
of more than two experimental groups. Differences between groups
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3.1. Conditional inactivation of Met in cardiomyocytes does not overtly
affect embryonic and postnatal heart development, but leads to cardiac
anomalies in adult mice
In order to study the role played in vivo by Met in cardiomyocytes
and to bypass embryonic lethality, we generated a mouse model with
a selective inactivation of Met signaling in cardiomyocytes. To do it,
we intercrossed the c-met ﬂoxed mouse, which carries c-met alleles
with exon 16 ﬂanked by loxP sites (c-metﬂ/ﬂ) [22] with a transgenic
mouse bearing the Cre recombinase under the α-MHC promoter [23].
The resulting α-MHCCre:metﬂ/ﬂ conditional knock-out will be herein
referred to as α-MHCMet-KO. Because some strains of transgenic
α-MHCCre mice expressing very high levels of Cre-recombinase in
cardiomyocytes have been described to present heart anomalies [30],
we checked the hearts from our α-MHCCre mice. They were similar to
c-metﬂ/ﬂ (considered as controls) in all experiments performed (Supple-
mentary Fig. 1). So, both were indistinctly used as controls.
Efﬁciency of the c-met deletion was determined by PCR and
Western-blot analysis. A deletion-speciﬁc fragment (650 bp) was am-
pliﬁed by PCR using DNA from E15.5 α-MHCMet-KO embryonic hearts.
Consistently, a sharp decrease in c-Met protein levels was also found
(Fig. 1a), conﬁrming the efﬁcient deletion of the Met ﬂoxed exon 16,
as previously shown in other tissue-speciﬁc Cre lines [22,31,32]. The
Met deletion was further conﬁrmed in adult hearts (data not shown).
Quantiﬁcation revealed aMet deletion of around70% and 90% in embry-
onic (E15.5) and adult α-MHCMet-KO hearts, respectively (data not
shown). The remaining Met expression corresponds most likely to
that present in non-cardiomyocyte cells. No signiﬁcant morphological
differences were found between control and α-MHC-Met-KO mutant
hearts, either during embryonic development or after birth (Fig. 1b
and c). These data indicate that Met signaling in cardiomyocytes is dis-
pensable for heart development.
Conditional α-MHCMet-KO mutants were born following a Mende-
lian ratio. They displayed a normal lifespan and weight curve (not
shown), thus indicating that other tissues had been preserved from
Met inactivation. Therefore, the α-MHCMet-KO mutant mice represent
a unique genetic setting to investigate Met signaling requirement for
heart function. This issue was assessed by performing a series of mor-
phological, molecular, and functional studies on 3-, 6-, and 9-month-
old α-MHCMet-KO mice. It is well know that the gender may inﬂuence
themolecular process underlying heart function, as shown by a number
of studies in mice [33–35]. We therefore ﬁrst focused our analyses on
α-MHCMet-KO males. Whereas morphological analysis of the heart
did not reveal signiﬁcant abnormalities in 3-month-old α-MHCMet-
KO males, we observed structural abnormalities in 6-month-old
α-MHCMet-KO mutant hearts (Fig. 2a, b, d). In particular, a signiﬁcant
increase in the cross-sectional area of cardiomyocytes was observed in
α-MHCMet-KOmutant hearts from 6- to 9-month-old males compared
to controls (Fig. 2b, c and Supplementary Fig. 2a). In addition,
myocardial ﬁbrosis, diffused in some places and more prominent
in deﬁned areas, with cardiomyocyte disorganization and strong
collagen deposition, was also found in the heart of 6- and 9-month-Fig. 2. Met inactivation in cardiomyocytes leads to cardiomyocyte hypertrophy, ﬁbrosis and a
6 months old) stained with hematoxylin/eosin (scale bar: 100 μm) (n = 5). b: Representativ
α-MHCMet-KO). c: Histogram showing the mean values ± SEM of the transverse cardio
α-MHCMet-KO are signiﬁcant (**p b 0.01, n = 5). d: Mallory's trichrome staining of collagen
bar: 200 μm). e: Histogram showing the mean values ± SEM of the ﬁbrotic cardiac surface in 6
pared with α-MHCMet-KO (n = 5). f: Immunolocalization of active caspase-3 in 6-month-old
active caspase 3 positive cells (right) (n = 4). Positive cells (arrows) can be observed in the ﬁ
desmin immunoreactivity (in green), suggesting they are apoptotic cardiomyocytes. Note the
and β-MHC mRNAs expression by RT-qPCR in hearts from 3- and 6-month-old males, compari
togram (n = 5). A signiﬁcant increase (***p b 0.001) is produced in 6-month-old α-MHCMe
mRNAs in 6-month-old mutant males as compared with controls detected by RT-qPCR analysiold α-MHCMet-KO males as compared to controls (Fig. 2d, e and
Supplementary Fig. 2b and c). As ﬁbrosis can be a physiological
response to cardiomyocyte death, we analyzed the presence of active
caspase-3 in heart sections. We found an increase in the percentage of
active caspase 3 positive cells, mainly on highly ﬁbrotic areas of hearts
from α-MHCMet-KOmales as compared to controls (Fig. 2f).
We next asked whether these morphological defects observed in
α-MHCMet-KOmaleswere parallel to heart dysfunctionmarkers. In par-
ticular, we performed RT-qPCR analyses to assess the levels of β-MHC
and atrial natriuretic factor (ANF) mRNAs, known to be induced during
hypertrophy [36,37]. No differenceswere observed in 3-month-oldmu-
tants (Fig. 2g). In contrast, we found increasedmRNAs expression levels
of ANF, and β-MHC in hearts of 6-month-old α-MHCMet-KO males as
compared to controls (Fig. 2g and Supplementary Fig. 1a). Moreover,
RT-qPCR expression analyses of pro-ﬁbrotic genes such as TGF-β2 and
TGF-β3, or ﬁbrotic markers such asα-smooth muscle actin (Acta-2) re-
vealed signiﬁcantly increased levels in α-MHCMet-KO males as com-
pared to controls (Fig. 2h).
We next assessedwhether thesemorphological andmolecular alter-
ations impacted the heart electrical function by performing electrocar-
diography (ECG) analyses. Typical non-sedated mice ECG shows a
J wave just after QRS complex, an almost isoelectric S-P interval and a
P wave [38]. This typical ECG was observed in control mice (Fig. 3a).
However, we found speciﬁc alterations in 6-month-old α-MHCMet-KO
males. Anomalies consisted in the reduction or disappearance of the
J wave [38] and a negative deﬂection of the S-P interval (−0.21 ±
0.02 mV, versus −0.09 ± 0.02 mV in control mice, p b 0.01), in con-
trast with the isoelectric S-P interval observed in control animals [38]
(Fig. 3a). Although visual inspection suggested also an increased P
wave in theα-MHCMet-KO comparedwith controlmalemice, a detailed
measurement of the wave amplitude (0.14 ± 0.02 mV in α-MHCMet-
KO and 0.12 ± 0.02 mV in control mice (p N 0.1)) showed no statisti-
cally signiﬁcant differences (Fig. 3a). However, data from echocardio-
graphic analyses demonstrated no signiﬁcant differences in cardiac
output or left ventricular mass in α-MHCMet-KO males (not shown).
In contrast, echocardiographic analyses of 9-month-old α-MHCMet-KO
males revealed signs of systolic dysfunction characterized by a signiﬁ-
cantly higher left ventricular systolic diameter and volume compared
to controls. Shortening fraction and ejection fraction were also signiﬁ-
cantly decreased (Fig. 3b and c). The LV posterior wall thickness/LV
end systolic dimension ratio was slightly lower in 9-month-old
α-MHCMet-KO males (0.56 ± 0.03) than in controls (0.66 ± 0.03,
p b 0.05), which suggests the existence of a left ventricular dilation.
Morphological, molecular, and functional studies were also
performed in females. Increased cardiomyocyte size and extensive
areas of ﬁbrosis were detected in 9-month-old α-MHCMet-KO females
(Supplementary Fig. 3a–c). Echocardiographic analysis revealed no sig-
niﬁcant differences between α-MHCMet-KO and controls, although a
similar tendency as that found in mutant males was observed (data
not shown). Together, these studies showed that HGF/Met signaling in
cardiomyocytes is dispensable during development and in young
mice, whereas it is required for proper heart function in adult mice.
Moreover, they indicate that males are more susceptible to an altered
HGF/Met signaling than females.poptosis in adult mice. a: Heart sections from control and α-MHCMet-KO males (3 and
e laminin immunostaining of heart sections from 6-month (mo) old males (control and
myocyte area in 6- and 9-month-old male hearts. Differences between control and
. Fibrotic areas (in blue) are present in 6-month-old α-MHCMet-KO male hearts (scale
- and 9-month-old male hearts (control and α-MHCMet-KO). **p b 0.01, control as com-
male hearts (left) and histogram showing the mean values ± SEM of the percentage of
brotic areas of α-MHCMet-KO hearts (scale bar: 25 μm). Some of them show remaining
depletion of desmin in cardiomyocytes from the ﬁbrotic areas. g: Quantiﬁcation of ANF
ngα-MHCMet-KO with controls of the same age. RQ values ± SEM are shown in the his-
t-KO males. h: Signiﬁcant increased (*p b 0.05) expression of TGF-β2, TGF-β3 and Acta2
s (mean RQ values ± SEM are shown, n = 3).
b
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Echocardiographic
Analysis Control males
α–MHCMet-
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n
Age (months)
4 4
9 9
Body weight (g) 53.73 ± ± 6.11
Heart rate (bpm) 680 ± ± 28.18
IVS (mm) 0.90 ± ± 0.00
LVPW (mm) 1.03 ± ± 0.07
LVDd (mm) 3.15 ± ± 0.12
LVDs (mm) 1.55 ± ± 0.03*
LVEDV (µl) 39.89 ± ± 3.72
LVESV (µl) 6.67 ± ± 0.44*
Stroke volumen (µl) 33.22 ± ± 3.29
Cardiac output 
(ml/min) 22.59 ± ± 2.95
Shortening fraction 
(%) 59.28 ± ± 1.76*
Ejection fraction (%) 92.65 ± ± 1.63*
LVM (mg) 84.01 ± ± 6.08
LVM/BW (mg/g) 1.56 ±
4.67 60.0
29.23 644
0.05 1.0
0.06 1.03
0.18 3.23
0.07 1.77
5.76 42.19
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Fig. 3. Conditional deletion of c-met in cardiomyocytes leads to heart dysfunction in 9-month-oldmice. a: Representative electrocardiogram (ECG) of anα-MHCMet-KO comparedwith a
control male (6 months old). The ﬁgure shows a negative deﬂection in the S-P segment (a) and a lower J wave (b). b: Echocardiography analysis in 9-month-old males. The following
parameters are shown: IVS, interventricular septum thickness; LVPW, left-ventricular posterior wall thickness; LVDd, left-ventricular diastolic dimension; LVDs, left-ventricular systolic
dimension; LVDEV, left-ventricular end-diastolic volume; LVESV, left-ventricular end-systolic volume; LVM, left ventricularmass. All data are expressed asmean ± SEM. *p b 0.05, control
as compared with α-MHCMet-KO. c: Representative echocardiographic images of an α-MHCMet-KO compared with a control male.
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cardiomyocytes, leading to an increase in ROS accumulation and altered
mitochondria in adult mice heart
The oxidative stress increases during aging, leading to cardiac alter-
ations, including hypertrophy and heart dysfunction [39]. As HGF/Met
signaling regulates the antioxidant defenses in different cells types by
preventing ROS accumulation [40–42], we investigated whether heart
defects observed in adult α-MHCMet-KOmales were linked to an imbal-
ance between pro- and anti-oxidant mechanisms. We found that pro-
tein levels of the antioxidant enzymes, catalase and SOD-2, were
reduced in the heart of 6- and 9-month-old α-MHCMet-KO males as
compared to controls (Fig. 4a and Supplementary Fig. 1b).
Consistently, catalase and SOD-2 activities were also decreased in α-
MHCMet-KOmales (Fig. 4b).We also found that reactive oxygen species
were accumulated in cardiomyocytes of α-MHCMet-KOmales as shown
by 2-hydroethidine staining and 4-OH-nonenal immunolocalization in
tissue sections from 6- to 9-month-old mice, respectively (Fig. 4c and
d). In addition, carbonylated protein levels increased in 6-month-old
mutant males (Fig. 4e), as a readout of proteins oxidation by ROS.
Because ROS accumulation can either be a consequence of an altered
mitochondrial function and/or lead tomitochondrial damage,wenext in-
vestigated whether α-MHCMet-KO 6-month-old male hearts presented
alterations in mitochondria. We found that the mitochondrial proteins,porin and cytochrome c were signiﬁcantly decreased in mutants as
compared to controls (Fig. 4f). Consistently, cytochrome c oxidase
activity was also reduced in α-MHCMet-KO hearts (Fig. 4g). In contrast,
we did not observe any alteration in anti-oxidant enzymes, ROS accumu-
lation, carbonylated proteins or mitochondrial proteins in 6-month-old
α-MHCMet-KO females, consistent with normal morphology and
function, as previously assessed (Supplementary Fig. 3). However, in
9-month-old mutant female hearts anti-oxidant enzymes levels signiﬁ-
cantly decreased and ROS accumulation was detected (Supplementary
Fig. 4c), according to the presence of ﬁbrosis and the increased
cardiomyocytes size (Supplementary Fig. 3). Altogether, these ﬁndings
strongly indicate that HGF/Met signalling is required for normal mito-
chondrial function and redox homeostasis in adult cardiomyocytes.
3.3. Met acts on p38 MAPK to increase antioxidant enzymes levels and
counteracts TGF-β effect in cardiomyocytes
We next aimed at uncovering the molecular mechanism by which
HGF/Met signaling in cardiomyocytes ensures proper levels of antioxidant
enzymes. As it has been shown that p38αMAPK regulates the expression
of SOD-2 and catalase in mouse embryonic ﬁbroblasts (MEFs) [43], we
determined P-p38MAPK levels, as a readout of p38 activity in control
and α-MHCMet-KO hearts. Notably, we found that P-p38MAPK levels
were signiﬁcantly decreased in 6- and 9-month-old mice α-MHCMet-KO
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p38α was required for HGF/Met-mediated regulation of antioxidant en-
zymes in cardiomyocytes through the use of pharmacological approaches
in genetically modiﬁed embryonic cardiomyocyte cell lines generated
from wt or p38α deﬁcient mice (p38α−/−). We found decreased
catalase and SOD-2 protein levels in p38α−/− as compared to wt
cardiomyocytes (Fig. 5b). Met inhibition with SU11274, detected by the
decrease in Met phosphorylation (Fig. 5b), reduced the levels of catalase,
SOD-2 and P-p38 MAPK in wt cells, but not in p38α−/− cells (Fig. 5b).
These ﬁndings were further conﬁrmed using neonatal cardiomyocytes(data not shown). Moreover, HGF stimulation increased the levels of cat-
alase, SOD-2 and P-p38 MAPK proteins in wt, but not in p38α−/−
cardiomyocytes (Fig. 5b). These ﬁndings indicate that HGF/Met acts
through p38 MAPK to increase catalase and SOD-2 levels. According to
this, an increase in the levels of carbonylated proteins was detected in
wt cardiomyocytes treated with SU11274 (Fig. 5c). HGF treatment
(alone) slightly decreased them. As expected, HGF had no effect when
used in combination with SU11274. Consistently, higher basal levels of
carbonylated proteins were found in p38α−/− cardiomyocytes as com-
pared to those of wt cells, which were further increased upon SU11274
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alone or in combination with SU11274).
The increased levels of TGF-β observed in α-MHCMet-KO hearts
(Fig. 2h) prompted us to investigate whether the levels of antioxidant
enzymes were inﬂuenced by TGF-β. We found that TGF-β led to adecrease in catalase and SOD-2 protein levels, mainly in wt
cardiomyocytes (Fig. 5d). Intriguingly, HGF counteracted the decrease
in catalase and SOD-2 protein levels mediated by TGF-β in wt
cardiomyocytes (Fig. 5d). Accordingly, HGF activated p38α, both in the
absence and presence of TGF-β (Fig. 5d). In agreement with all these
2212 M. Arechederra et al. / Biochimica et Biophysica Acta 1832 (2013) 2204–2215changes in SOD-2 and catalase expression, TGF-β increased the levels of
carbonylated proteins in wt cardiomyocytes (Fig. 5e). HGF slightly de-
creased them, but this effect was not statistically signiﬁcant. In
p38α−/− cardiomyocytes, TGF-β did not further increase its intrinsic
high basal levels of carbonylated proteins and HGF had no effect on
them.
Taken together, these ﬁndings indicate that HGF/Met acts through
p38α MAPK to increase the levels of antioxidant enzymes in cardio-
myocytes and to avoid ROS accumulation, thus partially counteracting
the effects elicited by TGF-β.
3.4. Increased cardiomyocyte size, occurring in the absence ofMet signaling,
is prevented by antioxidant treatment
As alteration of Met signaling in cardiomyocytes leads to decreased
antioxidant enzymes levels, it is tempting to speculate that accumula-
tion of ROS in α-MHCMet-KO hearts could be responsible for the in-
creased size of cardiomyocytes. This would be coherent with previous
studies showing that ROS accumulation is responsible for cardio-
myocyte hypertrophy as it was observed in cardiomyocytes isolated
from Sirt3-deﬁcient mice [44]. We therefore explored this hypothesis
using wild-type neonatal cardiomyocyte cell lines. Remarkably, we
found that Met inhibition led to an increase in cell size in a time-
dependent manner (Fig. 6a, b). Treatment of cardiomyocytes with the
antioxidant N-acetyl-cysteine partially prevented the increase in the
size of cells exposed to the Met inhibitor, SU11274 (Fig. 6a, b). These
ﬁndings support that ROS accumulationmight account for the hypertro-
phy of cardiomyocytes occurring in the absence of HGF/Met signaling.
Additionally, the fact that Met inhibition itself leads to an increase in
cardiomyocyte cell size suggests the existence of an autocrine signaling
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Genetically modiﬁed mouse models have unveiled several genes in-
volved in heart development and in regulation of adult heart physiology.
However, key players for adult heart function and homeostasis remain to
be uncovered. Their identiﬁcation would improve our understanding of
heart dysfunction, uncover new diagnostic markers and be instrumental
for therapy and/or regenerative interventions. HGF/Met is an attractive
signal as administration of exogenous HGF has a cardio-protective role
in models of heart damage [11–13]. By exploring in vivo the role played
by Met in heart during embryogenesis and in adulthood through selec-
tive inactivation of the met gene in cardiomyocytes, we demonstrated
that while it is not essential for heart development, Met is required for
heart homeostasis in adultmice. Intriguingly,Met becomes progressively
required during aging. Whereas 3-month-old α-MHCMet-KO mutant
hearts are normal, hearts from 6-month-old males show an increase
in cardiomyocyte size and myocardial ﬁbrosis. Molecular markers of
cardiac damage, such as ANF or β-MHC are up-regulated in α-MHCMet-
KO males. This is accompanied by abnormal ECG, characterized by a
marked depression of the S-P segment, a feature reported in rats with
isoproterenol-induced cardiac hypertrophy [45]. As age increases,
lack of HGF/Met signaling impacts heart function, so 9-month-old
α-MHCMet-KO males suffer left ventricle systolic dysfunction. In addi-
tion, taking into account that, although the LV posterior wall thickness/
LV end systolic dimension ratio is slightly lower in 9-month-old
α-MHCMet-KO than in wt males, the ventricular mass/body weight
ratio is similar, which suggests the existence of heart dilation rather
than hypertrophy. Heart dysfunction of α-MHCMet-KO mutants is
paralleled by a signiﬁcant reduction in protein levels and enzymatic
activities of catalase and SOD-2 in the heart of α-MHCMet-KO mutants,
accompanied by ROS accumulation. These alterations were found inSU NAC+SU
1 day
NAC+SU
1 day
4 days
***
uced byMet inhibition. Immortalized neonatalwt cardiomyocytesweremaintained in the
r 4 days as indicated. a: Representative phase-contrast microscopy images after 1 day of
ed as arbitrary units (***p b 0.001, n = 3).
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KO females is most likely due to the existence of estrogen-induced
cardio-protective mechanisms, which have been extensively studied
[33–35] and which might partially compensate HGF/Met requirement
for heart function in young females.
The cardio-protective role of Met during aging and in the absence of
experimentally induced damage is in agreement with the HGF/Met
properties reported in experimental models of human pathologies
such as myocardial infarction [11,13], ischemia/reperfusion injury [12],
or other models of cardiomyopathy, where ﬁbrosis is produced [15].
However, in all these studies it was not possible to clarify in which cell
types HGF/Met signaling was required, as HGF can activate Met in
most of the cell types present in the heart. Thus, some of the HGF effects
previously described could be mediated by Met activation in non-
cardiomyocyte cell types, such as ﬁbroblasts, coronary endothelium or
vascular smooth muscle. It is also important to highlight that HGF is a
potent pro-angiogenic factor and its effect promoting neovascularization
would be cardioprotective per se [16,46]. The inhibition of Met signaling
in myocardium, leaving intact the angiogenic roles of HGF on the coro-
nary endothelium, allows excluding that the observed phenotype can
be due to a vascular defect. Thus, our genetic mouse model determines
in vivo a cell autonomous requirement of HGF/Met signaling in
cardiomyocytes for their maintenance and function. Although our re-
sults clearly suggest a direct effect of HGF on mature cardiomyocytes,
we cannot formally exclude that HGF signaling may also inﬂuence the
expansion of cardiomyocyte progenitors as they express α-MHC [47].
In fact, the improved heart functionality induced by HGF treatment in
doxorubicin-induced cardiomyopathy [14] or the regeneration pro-
duced in an infarcted myocardium [48,49], could be explained by en-
hanced myocardial progenitor cells proliferation and/or migration. If
the effect on cardiomyocyte progenitors is conﬁrmed, HGF/Met signal-
ing would be not only cardioprotective, but also involved in cardiac
homeostasis.
The herein described property of HGF/Met signaling to protect
cardiomyocytes from ROS-induced damage is in agreement with previ-
ous studies performedunder non-physiological conditions. For example,
HGF protects cultured adult rat cardiomyocytes from apoptosis induced
by oxidative stress upon serum deprivation, treatment with daunorubi-
cin, or hydrogen peroxide [50]. A role for HGF preventing heart ﬁbrosis
has been previously described in the cardiomyopathic Syrian hamster
[15]. In this pathological model, HGF down-regulation in endothelial
and interstitial cells triggers TGF-β1 up-regulation and interstitial
ﬁbrosis, whereas HGF treatment decreases TGF-β1 expression and
suppressed ﬁbrosis. We show here that under physiological conditions,
HGF/Met signaling in cardiomyocytes is also essential to prevent ﬁbrosis
in adult heart. Furthermore, we demonstrate a negative correlation be-
tween Met activity and levels of pro-ﬁbrotic factors such as TGF-β2
and TGF-β3. We also provide evidence that TGF-β treatment leads to
down-regulation of antioxidant enzymes in cultured cardiomyocytes,
thus linking ﬁbrosis and oxidative stress.
The accumulation of ROS found inα-MHCMet-KOmutant hearts could
be responsible for their dysfunction, based on the well-known link be-
tween oxidative stress and heart failure [51]. Consistently, the oxidation
of several proteinsmight account for a reduced contractile heart capacity.
For example, proteins regulating the release and uptake of Ca by the en-
doplasmic reticulum, such as SERCA, or proteins involved in the regula-
tion of myoﬁlaments can be inactivated through oxidation, which leads
to a reduced contractile force [51,52]. In addition to the impact on
contractile capacity, ROS accumulation can induce cardiomyocyte cell
death [51]. The ability of HGF/Met to counteract SOD dysfunction in a
neurodegenerative animal model of amyotrophic lateral sclerosis [53]
and to regulate antioxidant defenses [40–42] has been reported. For
example, in vivo hepatocyte-speciﬁc Met deletion unbalances ROS regu-
lation and sensitizes cells to Fas-mediated apoptosis [40]. HGF treatment
also leads to increased mitochondrial activity and mass in glioblastoma
cells [54]. The link between increased ROS levels and mitochondrialdysfunction in defective hearts is supported by other studies
[51,52,55,56]. Therefore, it is tempting to speculate that mitochondrial
functional alterations occurring in Met deﬁcient cardiomyocytes could
cause inappropriate antioxidant capability, leading to increased oxidative
stress. It is also possible that the reduced contractile function observed in
the α-MHCMet-KO mice could be a consequence of the decrease in the
number of mitochondria and/or their functionality [52] as they are criti-
cal to provide ATP for contraction.
The effects of Met inactivation in cardiomyocytes partially resemble
heart defects in Sirt3-deﬁcient mice [44]. These mice present heart
ﬁbrosis and ROS accumulation as a consequence of the decrease in
catalase and SOD-2 expression in cardiomyocytes, but they also show
cardiac hypertrophy [44]. The capability of Sirt3 andMet to prevent car-
diac damage by suppressing ROS accumulation is in agreementwith the
lethality of SOD-2 deﬁcient mice a few days after birth due to dilated
cardiomyopathy, despite normal heart development [57]. It is also im-
portant to highlight that the contractile defect observed in the inducible
HGF transgenic (tg) mice shares certain similarities to the one induced
in α-MHCMet-KOmice [21]. Because in these HGF tg mice, the endoge-
nous Met receptor is downregulated, this might partially resemble our
mouse model lacking a functional Met receptor in cardiomyocytes.
However, different from the HGF tg mouse, HGF would not be over-
expressed in our α-MHCMet-KOmouse model.
Mechanistically, we provide in vivo and in vitro evidences supporting
a role for p38 MAPK in the antioxidant effect of HGF/Met in
cardiomyocytes. HGF increases SOD-2 and catalase expression and
prevents their down-regulation by TGF-β when p38α MAPK signaling
is intact. These ﬁndings are consistent with the previously reported
role of p38αMAPK as amediator of SOD-2 and catalase expression in re-
sponse to oxidative stress inMEFs [43]. These ﬁndings, togetherwith re-
cent studies on p38MAPK requirement for the survival effect of HGF in
embryonic and cancer cells [58,59], unveil unexpected requirements of
the p38MAPK pathway in cell regulation by receptor tyrosine kinases.
Our studies demonstrate a cell autonomous requirement of HGF/Met
signaling in cardiomyocytes to ensure heart function in adult mice by
preventing oxidative stress generation and ROS-induced damage. The
control of TGF-β production and p38α MAPK activity by the HGF/Met
axis appears to be essential for the maintenance of heart homeostasis.
Indeed, p38α MAPK appears to be an important mediator of HGF/Met
actions, as it is required for the up-regulation of antioxidant enzymes.
Notably, HGF not only regulates the production of TGF-β in the heart,
but also partially counteracts its effect on cardiomyocytes.
Our ﬁndings open a new perspective to further explore HGF/Met
as putative diagnostic markers of individuals subjective to heart
defects and therapeutic intervention to treat cases of idiopathic
cardiomyopathies.
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